BerGenBio has collaborated with several leading pharmaceutical companies and academic institutions to advance the development of bemcentinib. These Collaborators include:

BerGenBio retains full global development, marketing, and commercialization rights for its product candidates. As we further advance our selective small molecule AXL inhibitor bemcentinib (BGB324) and other drug candidates in our pipeline, we will seek partners to maximize clinical and commercial opportunities worldwide.

Contact partnering